These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 14526190)

  • 21. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
    Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
    Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
    Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
    J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease.
    Li SH; Yu ZX; Li CL; Nguyen HP; Zhou YX; Deng C; Li XJ
    J Neurosci; 2003 Jul; 23(17):6956-64. PubMed ID: 12890790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
    Wang H; Lim PJ; Karbowski M; Monteiro MJ
    Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioenergetics in Huntington's disease.
    Grünewald T; Beal MF
    Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease.
    Wang Y; Lin F; Qin ZH
    Neurosci Bull; 2010 Apr; 26(2):153-62. PubMed ID: 20332821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.
    Kim C; Yousefian-Jazi A; Choi SH; Chang I; Lee J; Ryu H
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Huntington's disease: translating a CAG repeat into a pathogenic mechanism.
    MacDonald ME; Gusella JF
    Curr Opin Neurobiol; 1996 Oct; 6(5):638-43. PubMed ID: 8937828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?
    Kennedy L; Shelbourne PF
    Hum Mol Genet; 2000 Oct; 9(17):2539-44. PubMed ID: 11030759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huntington's disease. Expanding horizons for treatment.
    McMurray CT
    Lancet; 2001 Dec; 358 Suppl():S37. PubMed ID: 11784586
    [No Abstract]   [Full Text] [Related]  

  • 34. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
    Shelbourne PF; Keller-McGandy C; Bi WL; Yoon SR; Dubeau L; Veitch NJ; Vonsattel JP; Wexler NS; ; Arnheim N; Augood SJ
    Hum Mol Genet; 2007 May; 16(10):1133-42. PubMed ID: 17409200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Huntington's disease.
    Roze E; Bonnet C; Betuing S; Caboche J
    Adv Exp Med Biol; 2010; 685():45-63. PubMed ID: 20687494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
    Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
    Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.
    Hölter SM; Stromberg M; Kovalenko M; Garrett L; Glasl L; Lopez E; Guide J; Götz A; Hans W; Becker L; Rathkolb B; Rozman J; Schrewed A; Klingenspor M; Klopstock T; Schulz H; Wolf E; Wursta W; Gillis T; Wakimoto H; Seidman J; MacDonald ME; Cotman S; Gailus-Durner V; Fuchs H; de Angelis MH; Lee JM; Wheeler VC
    PLoS One; 2013; 8(11):e80923. PubMed ID: 24278347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
    Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.